Edit
Secretome Therapeutics (formerly NeoProgen)
https://secretometx.com/Last activity: 07.09.2022
Probably Closed - Reference to Secretome Therapeutics
University of Maryland, Baltimore (UMB) startup, Secretome Therapeutics (formerly NeoProgen), is developing a novel cell-based therapy for people who experience a heart attack and patients with advanced heart failure. The company’s technology is developed from neonatal Cardiac Progenitor Cells (nCPCs) derived from tissue discarded during lifesaving heart surgery in babies with congenital heart conditions. UMB’s leading pediatric cardiac surgeon, Sunjay Kaushal, MD, PhD, and his lab have published groundbreaking work in preclinical studies that show nCPCs appear to be superior to other cell therapies being pursued by competing academic and commercial groups for functional markers of cardiovascular disease.
Investors 1
| Date | Name | Website |
| - | Maryland M... | momentum.u... |
Mentions in press and media 2
| Date | Title | Description |
| 07.09.2022 | University System of Maryland Names Mike Ravenscroft Managing Director of the Maryland Momentum Fund | Baltimore, Md. (Sept. 7, 2022) – The University System of Maryland (USM) has named Mike Ravenscroft as Managing Director of the Maryland Momentum Fund (MMF), a $16 million investment fund that supports early stage companies affiliated with ... |
| 16.10.2019 | NeoProgen Completes $1.5M Seed Financing With $245K Investment From USM Maryland Momentum Fund | University of Maryland, Baltimore (UMB), University of Maryland (UM) Ventures, and TEDCO’s Maryland Venture Fund have also invested in NeoProgen’s innovative cell-based therapy for cardiovascular disease. |